| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Dicyclanil targets the hormonal pathways that control the transition between larval stages in insects, specifically by mimicking or disrupting the action of ecdysteroids, the insect molting hormones. By interfering with these hormonal signaling cascades, the compound prevents normal molting and development, ultimately causing death before the insect can reach maturation. This mechanism is characteristic of insect growth regulators, which are considered more environmentally friendly than conventional neurotoxic insecticides because they target insect-specific developmental processes.
|
|---|---|
| ln Vitro |
In vitro, Dicyclanil has been studied for its effects on insect cell lines and larval development. The compound inhibits molting and developmental progression in cultured insect cells, with activity dependent on the presence of functional ecdysone receptor signaling pathways. In biochemical assays, Dicyclanil shows activity as a disruptor of ecdysteroid-mediated gene expression. The compound's effects are specific to insects and related arthropods, with no significant activity against mammalian cell lines. In vitro studies help elucidate the molecular mechanism of action of this insect growth regulator.
|
| ln Vivo |
In vivo, Dicyclanil is highly effective as a topical treatment for sheep to prevent blowfly strike (cutaneous myiasis). The compound is applied to the wool and skin of sheep, where it provides prolonged protection against larval infestation by Lucilia cuprina and other blowfly species. The insect growth regulator activity prevents the development of fly larvae that come into contact with treated animals. Dicyclanil has been evaluated in field studies and is registered for veterinary use in several countries. Its efficacy, safety, and residue profile have been reviewed by international regulatory bodies including JECFA.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Dicyclanil typically involve ecdysone receptor binding studies using insect cell extracts or recombinant ecdysone receptor proteins. Radioligand binding assays using labeled ecdysteroids can be employed to measure the compound's ability to compete for binding to the ecdysone receptor. Alternatively, reporter gene assays using insect cell lines transfected with ecdysone-responsive reporter constructs are used to assess the compound's ability to modulate ecdysone receptor-mediated transcription. These assays help characterize the molecular mechanism of Dicyclanil's insect growth regulator activity.
|
| Cell Assay |
In vitro cellular assays for Dicyclanil utilize insect cell lines such as Sf9 (Spodoptera frugiperda) or Drosophila melanogaster cell lines that express functional ecdysone receptors. Cells are treated with Dicyclanil at concentrations ranging from 0.1 to 100 µM, and effects on cell proliferation, differentiation, and gene expression are assessed. Reporter gene assays are used to measure the compound's modulation of ecdysone-responsive promoter activity. Cell viability assays are employed to determine the cytotoxic concentration range. These assays provide insight into the compound's insect-specific activity and mechanism of action.
|
| Animal Protocol |
In vivo animal experiments for Dicyclanil typically involve sheep as the target species for blowfly prevention. The compound is applied topically to the wool and skin at recommended doses, and animals are monitored for the development of blowfly strike under controlled conditions. In field efficacy studies, treated and untreated animals are exposed to natural fly challenge, and the incidence of myiasis is recorded. Residue studies are conducted to determine the persistence of Dicyclanil in wool, meat, and milk to establish withdrawal periods. Safety studies in target animals assess local tolerance and systemic effects following application.
|
| ADME/Pharmacokinetics |
Dicyclanil exhibits specific pharmacokinetic properties related to its topical application in sheep. Following application to the wool and skin, the compound is absorbed into the fleece and skin layers, where it provides prolonged protection against fly larvae. Systemic absorption is limited, with low concentrations detected in plasma and tissues. The compound is metabolized and eliminated primarily through urinary and fecal routes. Residue studies have established withdrawal periods for meat and milk to ensure food safety. The compound's persistence in wool provides extended protection against blowfly strike.
|
| Toxicity/Toxicokinetics |
Toxicology studies of Dicyclanil have been conducted to establish its safety for use in sheep and for human consumers of treated animal products. The compound has been evaluated by the Joint FAO/WHO Expert Committee on Food Additives (JECFA), which established a safety factor of 100. At recommended use levels, Dicyclanil is well-tolerated in sheep with no significant adverse effects. Residue levels in meat and milk are below established maximum residue limits. The compound shows no evidence of genotoxicity or carcinogenicity in standard assays. Ecotoxicology studies have assessed its effects on non-target organisms.
|
| Additional Infomation |
Dicyclanil is a pyrimidine-derived insect growth regulator used for the topical treatment of sheep to prevent blowfly strike caused by Lucilia cuprina. It functions by interfering with ecdysteroid-mediated molting and development pathways in insects. The compound has been evaluated by JECFA for veterinary drug residues in food. Dicyclanil is structurally similar to cyromazine and belongs to the class of insect growth regulators that target insect-specific developmental processes.
|
| Molecular Formula |
C8H10N6
|
|---|---|
| Molecular Weight |
190.2052
|
| Exact Mass |
190.096
|
| CAS # |
112636-83-6
|
| Related CAS # |
112636-83-6;
|
| PubChem CID |
3081364
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
543.6±60.0 °C at 760 mmHg
|
| Melting Point |
250.5-252.4ºC
|
| Flash Point |
282.6±32.9 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.681
|
| LogP |
-0.44
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
14
|
| Complexity |
242
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N([H])(C1=NC(=C(C#N)C(N([H])[H])=N1)N([H])[H])C1([H])C([H])([H])C1([H])[H]
|
| InChi Key |
PKTIFYGCWCQRSX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H10N6/c9-3-5-6(10)13-8(14-7(5)11)12-4-1-2-4/h4H,1-2H2,(H5,10,11,12,13,14)
|
| Chemical Name |
4,6-diamino-2-(cyclopropylamino)pyrimidine-5-carbonitrile
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~62.5 mg/mL (~328.58 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.2573 mL | 26.2867 mL | 52.5735 mL | |
| 5 mM | 1.0515 mL | 5.2573 mL | 10.5147 mL | |
| 10 mM | 0.5257 mL | 2.6287 mL | 5.2573 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
